Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

Fig. 4

Mutation frequencies and concurrent mutations (A) Landscape of concurrent mutations in the intention-to-treat population. (B) Progression-free survival (PFS) and overall survival (OS) in patients with disruptive and non-disruptive TP53 mutation. (C) PFS and OS in patients with concurrent mutations located in PI3K/AKT/mTOR or other pathways. (D) PFS and OS in patients with or without copy number variation (CNV).

Back to article page

Molecular Cancer

ISSN: 1476-4598